( SCOTTSDALE Ariz.--(BUSINESS WIRE)--Jun...)New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine,Health

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals of Internal Medicine has published the results of a two-year clinical study on the impact of genistein on bone loss. The paper, "Effects of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic Postmenopausal Women-A Randomized Trial," appears in the current issue (June 19, 2007) and details the safety and efficacy of genistein for the dietary management of osteopenia and osteoporosis. The paper reports a significant gain in bone density among patients taking genistein at both 12 and 24 months over both baseline and placebo.

Key study findings include:

-- Over 85 percent of the women in the study taking genistein showed a gain in bone density.

-- Patients taking genistein in addition to calcium and vitamin D showed a gain in bone density of approximately 3 percent per year over baseline and 6 percent per year over those taking the placebo.

-- No adverse events were reported in the study. All participants were monitored for vasomotor symptoms, vaginal bleeding, breast tenderness, endometrial thickness, depression, irritability, insomnia, and gastrointestinal (GI) symptoms, as well as for changes in hematologic, renal and liver function tests. No changes were noted in any of these parameters except for mild GI symptoms.

Patients in the test group of the study used 54 mg/day of highly purified genistein isolated from soy along with calcium and vitamin D. Principle Investigator for the study, Francesco Squadrito, M.D., Professor of Pharmacology and Head of Clinical Pharmacology, School of Medicine, University of Messina, Italy, explains that there were some interesting aspects to the study: "The placebo in this study was not an inactive pill; instead it was the current standard of care for osteopenia - calcium plus vitamin D. Unlike other research in this area, this study was controlled for soy intake and additional supplem
'"/>

Page: 1 2 3
Related medicine technology :

1. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
2. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
5. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
6. POZEN Announces Positive Outcome for PA 325 Proof of Concept Study
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types